PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 10, 2026Gynecologic Oncology1 citationsOpen Access

Expression of the antibody-drug conjugate targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma of the female genital tract

XZXiaoming ZhangJSJahanbanoo ShahryariLKLeandra G. Kingsley

Key Points

  • To investigate the expression of B7-H3, TROP2, CLDN6, and DLL3 in mesonephric-like adenocarcinoma.
  • Assess expression of B7-H3, TROP2, CLDN6, DLL3 in histological samples of mesonephric-like adenocarcinoma.
  • Categorized expression levels as high, frequent, rare, or low.
  • B7-H3 and TROP2 were expressed in all mesonephric-like adenocarcinoma samples.
  • CLDN6 was frequently expressed, while DLL3 expression was rare and generally low.

Abstract

First study of B7-H3, TROP2, CLDN6, and DLL3 in mesonephric-like adenocarcinoma. B7-H3 and TROP2 are expressed in all mesonephric-like adenocarcinoma. CLDN6 expression is frequent in mesonephric-like adenocarcinoma. DLL3 expression was rare and generally low in mesonephric-like adenocarcinoma. Findings support exploration of antibody drug conjugate therapies in these tumors.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a00205ec8f74e3340f9b371https://doi.org/10.1016/j.ygyno.2026.04.020
Ask AI
Helpful
Bookmark
Share
View Full Paper